HUP0004234A2 - Dolasztatin-15-származékok - Google Patents

Dolasztatin-15-származékok

Info

Publication number
HUP0004234A2
HUP0004234A2 HU0004234A HUP0004234A HUP0004234A2 HU P0004234 A2 HUP0004234 A2 HU P0004234A2 HU 0004234 A HU0004234 A HU 0004234A HU P0004234 A HUP0004234 A HU P0004234A HU P0004234 A2 HUP0004234 A2 HU P0004234A2
Authority
HU
Hungary
Prior art keywords
group
amino
mono
natural
derivatives
Prior art date
Application number
HU0004234A
Other languages
English (en)
Inventor
Teresa Barlozzari
Andreas Haupt
Bernd Janssen
Andreas Kling
Thomas Zierke
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HUP0004234A2 publication Critical patent/HUP0004234A2/hu
Publication of HUP0004234A3 publication Critical patent/HUP0004234A3/hu
Publication of HU228996B1 publication Critical patent/HU228996B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát az (I) általános képletű, a sejteknövekedését gátló peptid-származékok és ezek gyógyászatilagelfogadható savakkal alkotott savaddíciós sói képezik - ahol A, B, D,E, F, G és K jelentése természetes vagy nem-természetes aminosav-maradék; s és r értéke, egymástól függetlenül, egyaránt 0 vagy l; és Ljelentése egy vegyértékű gyök, például egy amino- vagy szubsztituáltaminocsoport, egy b-hidroxi-aminocsoport, egy hidrazidocsoport, egyalkoxicsoport, egy tioalkoxicsoport, egy amino-oxi-csoport vagy egyoximatocsoport. Ó
HU0004234A 1997-07-18 1998-07-07 Dolasztatin-15 származékok HU228996B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives
PCT/US1998/013901 WO1999003879A1 (en) 1997-07-18 1998-07-07 Dolastatin 15 derivatives

Publications (3)

Publication Number Publication Date
HUP0004234A2 true HUP0004234A2 (hu) 2001-05-28
HUP0004234A3 HUP0004234A3 (en) 2001-08-28
HU228996B1 HU228996B1 (hu) 2013-07-29

Family

ID=25406130

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004234A HU228996B1 (hu) 1997-07-18 1998-07-07 Dolasztatin-15 származékok

Country Status (33)

Country Link
US (6) US6143721A (hu)
EP (1) EP0991658B1 (hu)
JP (4) JP4508413B2 (hu)
KR (1) KR100579748B1 (hu)
CN (1) CN1268636C (hu)
AR (1) AR018501A1 (hu)
AT (1) ATE314387T1 (hu)
AU (1) AU750120B2 (hu)
BG (1) BG65212B1 (hu)
BR (1) BR9810911A (hu)
CA (1) CA2296036C (hu)
CO (1) CO4990967A1 (hu)
CY (1) CY1107047T1 (hu)
CZ (1) CZ303045B6 (hu)
DE (1) DE69832982T2 (hu)
DK (1) DK0991658T3 (hu)
ES (1) ES2258819T3 (hu)
HK (1) HK1029125A1 (hu)
HR (1) HRP980397A2 (hu)
HU (1) HU228996B1 (hu)
ID (1) ID24669A (hu)
IL (1) IL133784A (hu)
MY (1) MY135057A (hu)
NO (1) NO326827B1 (hu)
NZ (1) NZ502296A (hu)
PL (1) PL197884B1 (hu)
PT (1) PT991658E (hu)
RU (1) RU2195462C2 (hu)
SK (1) SK286581B6 (hu)
TR (2) TR200000132T2 (hu)
TW (1) TW533217B (hu)
WO (1) WO1999003879A1 (hu)
ZA (1) ZA986358B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686336B2 (en) 2000-02-08 2004-02-03 Federal Government As Represented By The Department Of Veterans Affaires N-terminal D(-)-penicillamine peptides as aldehyde sequestration agents
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CN1633289A (zh) 2002-03-22 2005-06-29 卫材株式会社 半星芒体衍生物及其用途
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
AU2003263964C1 (en) 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
SI1725249T1 (sl) 2003-11-06 2014-04-30 Seattle Genetics, Inc. Spojine monometilvalina, sposobne konjugacije na ligande
JP2008522624A (ja) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
RU2554087C2 (ru) * 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
ES2960619T3 (es) 2014-02-28 2024-03-05 Hangzhou Dac Biotech Co Ltd Enlazadores cargados y sus usos para la conjugación
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US20210308277A1 (en) 2016-11-14 2021-10-07 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
US5448045A (en) * 1992-02-26 1995-09-05 Clark; Paul C. System for protecting computers via intelligent tokens or smart cards
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
HUT71398A (en) * 1992-05-20 1995-11-28 Basf Ag Derivatives of dolastatin
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
DE69329425T2 (de) * 1992-12-16 2001-01-18 Basf Ag Dolastatin analog
US5554993A (en) * 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) * 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) * 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
CA2287379C (en) * 1997-01-10 2005-10-04 Silicon Gaming-Nevada Method and apparatus for providing authenticated, secure on-line communication between remote locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) * 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) * 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) * 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Also Published As

Publication number Publication date
JP2001515010A (ja) 2001-09-18
TR200000132T2 (tr) 2000-05-22
PT991658E (pt) 2006-05-31
AR018501A1 (es) 2001-11-28
KR20010021998A (ko) 2001-03-15
NZ502296A (en) 2002-02-01
US8163698B2 (en) 2012-04-24
AU8475898A (en) 1999-02-10
US20030153505A1 (en) 2003-08-14
CZ2000176A3 (en) 2001-06-13
JP5122429B2 (ja) 2013-01-16
EP0991658A1 (en) 2000-04-12
ID24669A (id) 2000-07-27
CN1264388A (zh) 2000-08-23
WO1999003879A1 (en) 1999-01-28
JP5047935B2 (ja) 2012-10-10
CA2296036C (en) 2007-05-01
HUP0004234A3 (en) 2001-08-28
AU750120B2 (en) 2002-07-11
ATE314387T1 (de) 2006-01-15
JP2009137968A (ja) 2009-06-25
CY1107047T1 (el) 2012-09-26
SK286581B6 (sk) 2009-01-07
US20100099843A1 (en) 2010-04-22
HRP980397A2 (en) 1999-04-30
TW533217B (en) 2003-05-21
ZA986358B (en) 2000-01-17
NO20000231L (no) 2000-01-17
CO4990967A1 (es) 2000-12-26
KR100579748B1 (ko) 2006-05-15
ES2258819T3 (es) 2006-09-01
IL133784A0 (en) 2001-04-30
US20060270606A1 (en) 2006-11-30
US7662786B2 (en) 2010-02-16
JP2012211164A (ja) 2012-11-01
HK1029125A1 (en) 2001-03-23
BR9810911A (pt) 2000-08-01
DE69832982D1 (de) 2006-02-02
US6143721A (en) 2000-11-07
IL133784A (en) 2005-09-25
US7084110B2 (en) 2006-08-01
DK0991658T3 (da) 2006-05-15
RU2195462C2 (ru) 2002-12-27
TR200103545T2 (tr) 2002-06-21
PL338144A1 (en) 2000-09-25
JP4508413B2 (ja) 2010-07-21
HU228996B1 (hu) 2013-07-29
CA2296036A1 (en) 1999-01-28
US20130046077A1 (en) 2013-02-21
DE69832982T2 (de) 2006-08-24
EP0991658B1 (en) 2005-12-28
SK187999A3 (en) 2000-09-12
MY135057A (en) 2008-01-31
US6458765B1 (en) 2002-10-01
PL197884B1 (pl) 2008-05-30
JP2009137967A (ja) 2009-06-25
CZ303045B6 (cs) 2012-03-07
BG104089A (en) 2000-12-29
CN1268636C (zh) 2006-08-09
BG65212B1 (bg) 2007-07-31
NO326827B1 (no) 2009-02-23
NO20000231D0 (no) 2000-01-17

Similar Documents

Publication Publication Date Title
HUP0004234A2 (hu) Dolasztatin-15-származékok
DK0720482T3 (da) Prosaposin og cytokin-afledte peptider som terapeutiske midler
ES2103857T3 (es) Peptidos ciclicos y su uso.
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
DK1188768T3 (da) LHRH-antagonisk-peptider
ES2058796T3 (es) Aislamiento y elucidacion estructural del depsipeptido citostatico lineal dolastatina 15.
DK0951474T3 (da) Nye cyclosporinderivater, deres fremstilling og farmaceutiske præparater deraf
DE69942035D1 (de) Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
AU667078B2 (en) Synthetic polypeptides as inhibitors of HIV-1
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
HUP0400988A2 (hu) Kombinált NEP/MP-gátló aktivitással rendelkező vegyületek felhasználása gyógyszerek előállítására
AU2003286404A1 (en) Peptide nanostructures, methods for their preparation and use
NO940299L (no) Peptid med organbeskyttende aktivitet
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
IT1276162B1 (it) Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE68917837D1 (de) Peptid-Verbindungen.
AU671989B2 (en) Treatment of tropical spastic paresis with peptide T
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
HUP0101715A2 (hu) Eljárások és készítmények reumatoid artritisz kezelésére
NO982100L (no) Peptid-derivater av Dolastatin 15 og deres anvendelse
ATE124955T1 (de) Substrat-peptide.
EP1074264A4 (en) NEOVASCULARIZATION INHIBITORS
ATE216706T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
NO20004613L (no) FremgangsmÕte for fremstilling av et tetrapeptid

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI IRODA, HU

Representative=s name: RATHONYI ZOLTAN, S.B.G. & K. SZABADALMI UEGYVI, HU

FH92 Termination of representative

Representative=s name: BELICZAY LASZLO, S.B.G. & K. BUDAPESTI NEMZETK, HU

GB9A Succession in title

Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG, DE

Free format text: FORMER OWNER(S): BASF AG, DE; ABBOTT GMBH & CO. KG, DE

MM4A Lapse of definitive patent protection due to non-payment of fees